On 12 February 2026, Pharmacy Daily announced that Arrotex Pharmaceuticals and Pfizer Australia have entered into a commercial partnership for Enbrel® (etanercept) in Australia. Under the agreement, Arrotex will be responsible for representing Pfizer’s Enbrel® across Australian pharmacies, hospital, and prescriber channels.
Enbrel® is approved for arthritis and psoriasis indications and was listed on the PBS in June 2003. There are multiple etanercept biosimilars in the Australian market listed on the PBS, including Sandoz’s Erelzi® (approved November 2017, PBS-listed as of October 2025), Biocon Biologics’ Nepexto® (launched in July 2025, PBS-listed as of July 2025) and Samsung Bioepis’ Brenzys®, which was previously distributed in Australia by Arrow Pharmaceuticals (approved by TGA in July 2016, PBS-listed as of April 2017).
In May 2022, Pfizer sued Samsung Bioepis and other companies involved in the commercialisation of Brenzys® in Australia, including Arrow Pharmaceuticals, for alleged infringement of AU 2005280034 (expired September 2025), relating to the production of etanercept. Samsung Bioepis and Organon (currently named in the Brenzys® Product Information as the Australian distributor) cross-claimed alleging that the AU 034 patent is invalid. A hearing took place in September and October 2025, with the judgment yet to be delivered by the Federal Court of Australia.